Real-World Cost-Effectiveness of Bevacizumab With First-Line Combination Chemotherapy in Patients With Metastatic Colorectal Cancer: Population-Based Retrospective Cohort Studies in Three Canadian Provinces

Background. Real-world evidence can be a valuable tool when clinical trial data are incomplete or uncertain. Bevacizumab was adopted as first-line therapy for metastatic colorectal cancer (mCRC) based on significant survival improvements in initial clinical trials; however, survival benefit diminish...

Descripción completa

Detalles Bibliográficos
Autores principales: Pataky, Reka E., Beca, Jaclyn, Tran, David, Dai, Wei Fang, Dvorani, Erind, Isaranuwatchai, Wanrudee, Peacock, Stuart, Alvi, Riaz, Cheung, Winson Y., Earle, Craig C., Gavura, Scott, Chan, Kelvin K. W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8216386/
https://www.ncbi.nlm.nih.gov/pubmed/34212111
http://dx.doi.org/10.1177/23814683211021060

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8216386/
https://www.ncbi.nlm.nih.gov/pubmed/34212111
http://dx.doi.org/10.1177/23814683211021060

Ejemplares similares